Probiotics, probioceuticals, pharmabiotics, psychobiotics, immunobiotics, eubiotics, post-biotics...
From Probiotics to Post-biotics - What's in a name?
Expert panel discussion on terms and meanings around probiotics…
We shall interactively discuss at this year's IPC, whether the evolving terminology around probiotics still makes sense, and whether consensus can be reached in their use.
Key questions to be addressed by experts:
- Do we need subcategories of probiotics? If Yes, based on what grounds?
- What would be the legislative impact of subcategories of probiotics (global view - USA, Europe, Asia)
- Should supporting research be different for these categories?
- DEFINITION: Do we need subcategories of probiotics? If Yes, based on what grounds?
‘Probiotics, probioceuticals, pharmabiotics, psychobiotics, immunobiotics, eubiotics, post-biotics...’, do you have idea of further subcategories? Please, contact us and suggest keywords for the definitions…
- GEOGRAPHY: What would be the legislative impact of subcategories of probiotics
(in the USA, Europe, Asia)
The purpose is to evaluate what would be the impact if a company would like to launch a product world-wide…
- RESEARCH: Should supporting research be different for these categories?
Would different names or ‘types’ of ‘probiotics’ also require different types / quality of scientific support? If yes, should we be able to define these requirements (efficacy, safety, target population (healthy/sick; age; nationality), dose, matrix, …)
- MARKETING: Should industry be able to communicate on the different categories and should the legislator determine/actively control the limits of these communications?
The reason to have the discussion has to do with the international differences that currently exist. EU versus Switzerland, Canada and other countries where legal health claims are allowed. Even within Europe there are differences on how the European legislation is implemented (Italy versus Ireland)…
- ECONOMY: Is valorization of the results of microbiota research really hampered by the current communication strategy in Europe?
As shown in a number of papers, Europe is missing opportunities to significantly reduce health care costs...
What's in name? - Expert panel discussion on the terms and meanings around probiotics
Bruno Pot - chair, Director of Business Development, Laboratory of Lactic Acid Bacteria & Mucosal Immunity, Institut Pasteur de Lille, Center for Infection & Immunity of Lille, France
Carine Lambert, International Probiotics Association - IPA Europe
David A. Mills, Peter J. Shields Endowed Chair in Dairy Food Science, Department of Food Science and Technology, University of California, Davis, USA
Linda Mulder, Winslove Probiotics, The Netherlands
Magali Cordillat Simmons, Pharmabiotic Research Centre, France
Sin-Hyeog IM - President of IPC2016
Institute for Basic Science (IBS) and POSTECH, South Korea